1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hemagen Diagnostics, Inc.

Hemagen Diagnostics, Inc.

HMGN
Hemagen Diagnostics, Inc.US flagOther OTC
0.00
USD
- -
- -
3,100.00Market Cap
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
TTM
Revenue per Share
1.14
1.13
0.95
0.84
0.74
0.5
0.31
0.29
0.42
0.36
0.34
0.33
- -
0.26
Basic EPS, GAAP
-0.53
-0.23
-0.18
-0.13
-0.36
-0.09
0.02
-0.06
0.03
-0.05
-0.01
-0.06
- -
-0.06
Free Cash Flow per Basic Share
-0.24
- -
- -
0.04
-0.02
-0.09
-0.05
-0.04
-0.01
-0.01
-0.02
-0.03
- -
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.4
-1.62
-1.74
-1.86
-2.21
-1.56
-1.53
-1.59
-1.56
-1.61
-1.6
-1.66
- -
-1.71
Tangible Book Value per Share
0.58
0.49
0.32
0.18
0.01
-0.07
-0.05
-0.1
-0.07
-0.12
-0.12
-0.17
- -
-0.23
Basic Weighted Avg Shares
10
10
10
10
10
15
15
15
15
15
15
15
- -
15
Sales/Revenue/Turnover
11
11
9
8
7
8
5
4
6
5
5
5
4
4
Operating Margin (%)
-38.63
-2.4
-7.06
2.89
-7.62
-9.53
-3.46
-3.54
1.85
-6.44
4.52
-9.19
-10.83
-10.83
Depreciation Expense
1
1
1
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-5
-2
-2
-1
-4
-1
- -
-1
- -
-1
- -
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
25.85
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-46.66
-20.04
-18.53
-14.93
-48.18
-17.63
6.55
-18.94
6.7
-14.91
-2.99
-17.13
-22.45
-22.45
Working Capital
3
4
3
4
3
2
3
2
-2
1
2
1
- -
- -
LT Debt
1
2
2
3
4
4
4
4
- -
4
4
4
4
4
Total Equity
6
5
3
2
- -
-1
-1
-1
-1
-2
-2
-3
-4
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-3.52
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-1.63
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
ST Debt
1
1
1
LT Borrowings
4
4
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
- -
1
1

Working Capital

FRC

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-41.69%
23.49%
32.37%
Free Cash Flow
-55.71%
28.59%
14.26%
Net Income, GAAP
-45.53%
-10.76%
3.05%
Sales/Revenue/Turnover
-6.37%
0.1%
-21.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
1
1
1
1
5
2011
1
1
1
1
5
2012
1
1
1
1
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
-0.01
- -
- -
- -
-0.01
2011
-0.01
-0.02
- -
- -
-0.06
2012
-0.02
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
William Hales
Full Time Employees
15
Sector
Healthcare
Industry
Biotechnology
Address
9033 Red Branch Road Columbia MD United States of America 21045
IPO Date
Feb 4, 1993
Website
hemagen.com
Similar Companies
ArcticZymes Technologies ASA (AZT.OL)
CureVac N.V. (5CV.DE)
Hvsen Biotechnology Co., Ltd. (300871.SZ)
Polus BioPharm Inc. (007630.KS)
MedMira Inc. (MIR.V)
Anixa Biosciences, Inc. (ANIX)
Business
Hemagen Diagnostics, Inc. (HMGN) develops, manufactures, and markets FDA-cleared diagnostic test kits and systems for human and veterinary clinical applications worldwide. The company offers its proprietary VIRGO line of immunoassays for diagnosing autoimmune and infectious diseases, as well as acute phase proteins; gold standard indirect fluorescent antibody (IFA) products; easy-to-use enzyme-linked immunosorbent assay (ELISA), hemagglutination (HA), and point-of-care (POC) testing solutions; clinical chemistry reagents; and analyzers such as the Analyst and Endocheck for measuring constituents in human and animal blood. Its veterinary diagnostics segment provides compact systems, equipment, reagents, supplies, and accessories for chemistry, hematology, and electrolyte testing in animal health practices, while human diagnostics target laboratories, hospitals, blood banks, and physicians' offices through direct sales and distributors. Founded in 1985 by scientists from the Boston University School of Medicine and headquartered at 9033 Red Branch Road, Columbia, Maryland, the company operates primarily in the biotechnology and health care equipment sectors, with a strategic emphasis on veterinary clinical diagnostics alongside its established human immunoassay portfolio. Hemagen has restructured and refocused its operations in recent years to prioritize veterinary diagnostics expansion through internal initiatives and collaborations, while maintaining its VIRGO human clinical diagnostic offerings for autoimmune and infectious diseases.